Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
Conditions
Keywords
Carcinoma, Renal Cell
Brief summary
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docetaxel and ramucirumab; or docetaxel and icrucumab.
Interventions
DRUGDocetaxel
Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
BIOLOGICALRamucirumab DP
Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
BIOLOGICALIcrucumab
12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis * Locally advanced or metastatic and unresectable transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis * Had treatment with a platinum-containing regimen * Disease progression within 12 months of after receiving the last dose of a platinum containing regimen in the neoadjuvant or adjuvant setting, and/or had disease progression while on a platinum-containing regimen or within 12 months after the last dose of therapy in the locally advanced or metastatic setting * Has measurable or nonmeasurable disease * Life expectancy of ≥ 3 months * Received no more than 2 prior systemic chemotherapy regimens in any setting * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Has adequate hematologic, coagulation, hepatic and renal function * Does not have: * cirrhosis at a level of Child-Pugh B (or worse) * cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis * If female, is surgically sterile, postmenopausal, or compliant with a highly effective contraceptive method during and for 12 weeks after the treatment period * If male, the patient is surgically sterile or compliant with a contraceptive regimen during and for 12 weeks after the treatment period
Exclusion criteria
* Received more than one prior systemic treatment regimen for metastatic disease * Received prior systemic taxane therapy (except for prior paclitaxel therapy) for Transitional Cell Carcinoma of the bladder, urethra, ureter, or renal pelvis in any setting (neoadjuvant, adjuvant, metastatic). Prior intravesical taxane therapy is allowed * Has received more than one prior anti-angiogenic agent for Transitional Cell Carcinoma of the bladder, urethra, ureter, or renal pelvis * Has received radiation therapy within 4 weeks prior to randomization * Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders * Has experienced a Grade ≥ 3 bleeding event (eg, via gastric ulcers, gastric varices, or gross hematuria) within 3 months prior to randomization * Has uncontrolled intercurrent illness including, but not limited to symptomatic anemia, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders * Has experienced any arterial thrombotic or thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack or cerebrovascular accident, within 6 months prior to randomization * Has known brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease * Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy * Has known human immunodeficiency virus infection or acquired immunodeficiency syndrome * Has received a prior autologous or allogeneic organ or tissue transplantation * Received chemotherapy within 21 days prior to randomization; and/or is currently enrolled in, or discontinued within 21 days prior to randomization from, a clinical trial involving an investigational product or unapproved use of a drug or device (other than the study drug\[s\] used in this study), or is concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study; and/or was treated with anti-angiogenic therapy within 28 days prior to randomization * Has undergone major surgery within 28 days prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization * Has had a serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization * Has an elective or planned major surgery to be performed during the course of the trial * Is pregnant or lactating * Has a concurrent active malignancy other than adequately treated non-melanomatous skin cancer, curatively treated cervical carcinoma in-situ, other noninvasive carcinoma or in-situ neoplasm, or prostate cancer with an undetectable prostate specific antigen (PSA) and no current treatment with hormone therapy * Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention * History of gastrointestinal perforation and/or fistula within 6 months prior to randomization * Has active diverticulitis * Known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80 * Known hypersensitivity to agents of similar biologic composition as ramucirumab DP, IMC-18F1, or other agents that specifically target vascular endothelial growth factor receptor (VEGF)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | Randomization to Measured PD or Death From Any Cause (Up To 40 Months) | PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response | First Criteria Met for CR or PR to Measured PD or Death From Any Cause (Up to 40 Months) | The duration of response was measured from the time measurement criteria were first met for a CR or PR (whichever was first recorded) until the first date of objectively documented progressive disease (taking as a reference for progressive disease the smallest measurement recorded since randomization) or the date of death, whichever occurred first. Data for participants who did not relapse or die were censored at the day of their last adequate tumor assessment. Duration of response was estimated by the Kaplan-Meier method. |
| Number of Participants With Adverse Events (AEs) | Up To 41.7 Months | A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section. |
| Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab | Cycle 1:Predose,1 hour(hr) post End of Infusion (EOI),48hr,72hr,168hr,336hr post-EOI;Cycle2:Predose,1hr post-EOI; Cycle3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI; Cycle4:Predose,1hr post-EOI;Cycle6 and every other cycle thereafter:Predose,1hr Post EOI | — |
| PK: Minimum Concentration (Cmin) Ramucirumab | Cycle 2:Predose,1hr post-EOI;Cycle3:Predose,1hr,48hr,72hr,168hr,336hr, post-EOI;Cycle4:Predose,1hr post-EOI;Cycle6:Predose,1hr Post EOI | — |
| PK: Cmax Icrucumab | Cycle 1:Predose,1 hr post-EOI, 48hr, 72hr Post-EOI; Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI | — |
| PK: Cmin Icrucumab | Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI | — |
| Percentage of Participants Achieving Objective Response Rate (ORR) | Randomization to Measured PD (Up to 40 Months) | Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \[if tumor markers were initially above the upper limit of normal (ULN)\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\*100. |
| Number of Participants With Serum Anti-Icrucumab Antibody Assessment | Cycle 1 Day 1 and Day 8 Predose and 1hr Post Dose | A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals. |
| Pharmacodynamics (PD): Change in Circulating Levels of Placental Growth Factor (PlGF) | 40 months | — |
| PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-A (VEGF-A) | 40 months | — |
| PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-B (VEGF-B) | 40 months | — |
| PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-1 (VEGFR-1) | 40 months | — |
| PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-2 (VEGFR-2) | 40 months | — |
| Number of Participants With Serum Anti-Ramucirumab Antibody Assessment | Cycle 1:Predose,EOI,1hr,48hr,72hr,168hr,336 hr post-EOI:Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI;Cycle 4:Predose,1hr post-EOI;Cycle 6:Predose,1hr post-EOI | Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals. |
Countries
Canada, United States
Participant flow
Pre-assignment details
Participants who died or discontinued treatment due to progressive disease (PD) were considered completers at the end of study. 8 participants were included in the never treated group due to death, PD, withdrawal, physician decision or protocol violation.
Participants by arm
| Arm | Count |
|---|---|
| Docetaxel Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle | 45 |
| Docetaxel + Ramucirumab DP Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle
Ramucirumab (DP): 10 mg/kg IV on day 1 of each 21-day cycle | 46 |
| Docetaxel + Icrucumab Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle
Icrucumab: 12 mg/kg IV on day 1 and Day 8 of each 21-day cycle | 49 |
| Total | 140 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 0 | 0 |
| Overall Study | Never Treated Death | 0 | 1 | 0 |
| Overall Study | Never Treated PD | 0 | 1 | 0 |
| Overall Study | Physician Decision | 1 | 0 | 0 |
| Overall Study | Protocol Violation | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 6 | 2 | 3 |
Baseline characteristics
| Characteristic | Docetaxel | Total | Docetaxel + Icrucumab | Docetaxel + Ramucirumab DP |
|---|---|---|---|---|
| Age, Continuous | 66.6 years STANDARD_DEVIATION 11.45 | 65.7 years STANDARD_DEVIATION 10.33 | 64.1 years STANDARD_DEVIATION 10.38 | 66.7 years STANDARD_DEVIATION 9.06 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 9 Participants | 2 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 41 Participants | 131 Participants | 47 Participants | 43 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 5 Participants | 11 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 4 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 4 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 36 Participants | 121 Participants | 42 Participants | 43 Participants |
| Region of Enrollment Canada | 30 Participants | 95 Participants | 37 Participants | 28 Participants |
| Region of Enrollment United States | 15 Participants | 45 Participants | 12 Participants | 18 Participants |
| Sex: Female, Male Female | 10 Participants | 30 Participants | 11 Participants | 9 Participants |
| Sex: Female, Male Male | 35 Participants | 110 Participants | 38 Participants | 37 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 45 / 45 | 46 / 46 | 49 / 49 |
| serious Total, serious adverse events | 19 / 45 | 25 / 46 | 22 / 49 |
Outcome results
Primary
Progression-Free Survival (PFS)
PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.
Time frame: Randomization to Measured PD or Death From Any Cause (Up To 40 Months)
Population: All randomized participants who received at least one dose of study drug. Participants censored: docetaxel arm = 40; docetaxel and ramucirumab arm = 34; docetaxel and Icrucumab arm = 41.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Docetaxel | Progression-Free Survival (PFS) | 2.8 months |
| Docetaxel + Ramucirumab DP | Progression-Free Survival (PFS) | 5.4 months |
| Docetaxel + Icrucumab | Progression-Free Survival (PFS) | 1.6 months |
Secondary
Duration of Response
The duration of response was measured from the time measurement criteria were first met for a CR or PR (whichever was first recorded) until the first date of objectively documented progressive disease (taking as a reference for progressive disease the smallest measurement recorded since randomization) or the date of death, whichever occurred first. Data for participants who did not relapse or die were censored at the day of their last adequate tumor assessment. Duration of response was estimated by the Kaplan-Meier method.
Time frame: First Criteria Met for CR or PR to Measured PD or Death From Any Cause (Up to 40 Months)
Population: All randomized participants received one dose of study drug and had CR or PR.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Docetaxel | Duration of Response | 4.6 months |
| Docetaxel + Ramucirumab DP | Duration of Response | 4.6 months |
| Docetaxel + Icrucumab | Duration of Response | NA months |
Secondary
Number of Participants With Adverse Events (AEs)
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Up To 41.7 Months
Population: All randomized participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Docetaxel | Number of Participants With Adverse Events (AEs) | Any AE | 45 Participants |
| Docetaxel | Number of Participants With Adverse Events (AEs) | Any SAE | 19 Participants |
| Docetaxel + Ramucirumab DP | Number of Participants With Adverse Events (AEs) | Any AE | 46 Participants |
| Docetaxel + Ramucirumab DP | Number of Participants With Adverse Events (AEs) | Any SAE | 25 Participants |
| Docetaxel + Icrucumab | Number of Participants With Adverse Events (AEs) | Any AE | 49 Participants |
| Docetaxel + Icrucumab | Number of Participants With Adverse Events (AEs) | Any SAE | 22 Participants |
Secondary
Number of Participants With Serum Anti-Icrucumab Antibody Assessment
A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals.
Time frame: Cycle 1 Day 1 and Day 8 Predose and 1hr Post Dose
Population: Zero participants analyzed. Data not collected.
Secondary
Number of Participants With Serum Anti-Ramucirumab Antibody Assessment
Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.
Time frame: Cycle 1:Predose,EOI,1hr,48hr,72hr,168hr,336 hr post-EOI:Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI;Cycle 4:Predose,1hr post-EOI;Cycle 6:Predose,1hr post-EOI
Population: All randomized participants who received at least one dose of study drug and had baseline and post baseline anti-ramucirumab antibodies.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Docetaxel | Number of Participants With Serum Anti-Ramucirumab Antibody Assessment | 1 Participants |
Secondary
PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-1 (VEGFR-1)
Time frame: 40 months
Population: Zero participants analyzed. Data not collected.
Secondary
PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-2 (VEGFR-2)
Time frame: 40 months
Population: Zero participants analyzed. Data not collected.
Secondary
PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-A (VEGF-A)
Time frame: 40 months
Population: Zero participants analyzed. Data not collected.
Secondary
PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-B (VEGF-B)
Time frame: 40 months
Population: Zero participants analyzed. Data not collected.
Secondary
Percentage of Participants Achieving Objective Response Rate (ORR)
Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \[if tumor markers were initially above the upper limit of normal (ULN)\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\*100.
Time frame: Randomization to Measured PD (Up to 40 Months)
Population: All randomized participants who received one dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Docetaxel | Percentage of Participants Achieving Objective Response Rate (ORR) | 8.9 percentage of participants |
| Docetaxel + Ramucirumab DP | Percentage of Participants Achieving Objective Response Rate (ORR) | 23.9 percentage of participants |
| Docetaxel + Icrucumab | Percentage of Participants Achieving Objective Response Rate (ORR) | 12.2 percentage of participants |
Secondary
Pharmacodynamics (PD): Change in Circulating Levels of Placental Growth Factor (PlGF)
Time frame: 40 months
Population: Zero participants analyzed. Data not collected.
Secondary
Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab
Time frame: Cycle 1:Predose,1 hour(hr) post End of Infusion (EOI),48hr,72hr,168hr,336hr post-EOI;Cycle2:Predose,1hr post-EOI; Cycle3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI; Cycle4:Predose,1hr post-EOI;Cycle6 and every other cycle thereafter:Predose,1hr Post EOI
Population: All randomized participants who received at least one dose of study drug and had evaluable PK data for Ramucirumab and there was no PK data for Docetaxel arm.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Docetaxel | Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab | Cycle 1 | 258 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 27 |
| Docetaxel | Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab | Cycle 2 | 304 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 31 |
| Docetaxel | Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab | Cycle 3 | 300 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 13 |
| Docetaxel | Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab | Cycle 4 | 279 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 40 |
| Docetaxel | Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab | Cycle 6 | 252 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 57 |
Secondary
PK: Cmax Icrucumab
Time frame: Cycle 1:Predose,1 hr post-EOI, 48hr, 72hr Post-EOI; Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
Population: All randomized participants who received at least one dose of study drug and had evaluable PK data for Icrucumab and there was no PK data for Docetaxel arm.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Docetaxel | PK: Cmax Icrucumab | Cycle 1 Cmax | 474 ug/mL | Geometric Coefficient of Variation 45 |
| Docetaxel | PK: Cmax Icrucumab | Cycle 3 Cmax | 599 ug/mL | Geometric Coefficient of Variation 27 |
Secondary
PK: Cmin Icrucumab
Time frame: Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
Population: All randomized participants who received at least one dose of study drug and had evaluable PK data for Icrucumab and there was no PK data for Docetaxel arm.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Docetaxel | PK: Cmin Icrucumab | Day 1 Cycle 2 | NA ug/mL | — |
| Docetaxel | PK: Cmin Icrucumab | Day 1 Cycle 3 | 153 ug/mL | Geometric Coefficient of Variation 66 |
Secondary
PK: Minimum Concentration (Cmin) Ramucirumab
Time frame: Cycle 2:Predose,1hr post-EOI;Cycle3:Predose,1hr,48hr,72hr,168hr,336hr, post-EOI;Cycle4:Predose,1hr post-EOI;Cycle6:Predose,1hr Post EOI
Population: All randomized participants who received at least one dose of study drug and had evaluable PK data for Ramucirumab and there was no PK data for Docetaxel arm.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Docetaxel | PK: Minimum Concentration (Cmin) Ramucirumab | Cycle 2 | 19.5 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 56 |
| Docetaxel | PK: Minimum Concentration (Cmin) Ramucirumab | Cycle 3 | 39.9 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 34 |
| Docetaxel | PK: Minimum Concentration (Cmin) Ramucirumab | Cycle 4 | 35.3 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 60 |
| Docetaxel | PK: Minimum Concentration (Cmin) Ramucirumab | Cycle 6 | 31.2 microgram/milliliter (ug/mL) | Geometric Coefficient of Variation 61 |